Education
About Us
Working with TipRanks
Follow Us
BIO-key International Inc (BKYI)
NASDAQ:BKYI
Top Page
BIO-key International
(NASDAQ:BKYI)
Select Model
Select Model
Rating:47Neutral
Price Target:
$0.76
▼(-13.98% Downside)
BIO-key International's overall score reflects significant financial challenges and poor valuation metrics. While technical indicators and earnings call insights provide some optimism, the company's financial position remains a primary concern. Recent corporate events improve liquidity, but strategic actions are needed to stabilize and enhance financial performance.
BIO-key International (BKYI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.10M
Dividend YieldN/A
Average Volume (3M)18.12M
Price to Earnings (P/E)―
Beta (1Y)1.14
Revenue Growth-1.19%
EPS Growth86.72%
CountryUS
Employees41
SectorN/A
Sector StrengthN/A
IndustrySecurity & Protection Services
Share Statistics
EPS (TTM)-0.15
Shares Outstanding10,836,618
10 Day Avg. Volume249,370
30 Day Avg. Volume18,118,550
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.75
Price to Sales (P/S)0.95
P/FCF Ratio-2.26
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue0.66
Enterprise Value/Gross Profit0.84
Enterprise Value/Ebitda-1.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.5
Revenue Forecast (FY)$7.30M
BIO-key International Business Overview & Revenue Model
Company DescriptionBIO-key International (BKYI) is a provider of biometric identification and authentication solutions, specializing in secure access management for businesses and government entities. The company operates primarily in the cybersecurity sector, offering a range of products that include fingerprint biometric scanners, identity management software, and mobile biometric solutions. BIO-key's technology is designed to enhance security, streamline user authentication processes, and improve operational efficiency across various industries.
How the Company Makes MoneyBIO-key generates revenue through multiple streams, including the sale of biometric hardware and software solutions, subscription-based services, and licensing fees for its technology. The company offers both on-premises and cloud-based solutions, catering to different customer needs. Key revenue streams come from direct sales to end-users, as well as partnerships with system integrators and value-added resellers who help distribute BIO-key's products. Additionally, the company may benefit from maintenance contracts and support services, which provide ongoing revenue beyond initial product sales. Strategic collaborations with other technology firms also enhance its market reach and revenue potential.
BIO-key International Earnings Call Summary
Earnings Call Date:Nov 14, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Mar 26, 2026
Earnings Call Sentiment Neutral
The earnings call reflects a company with promising growth opportunities, particularly in the defense sector, and strong customer retention, evidenced by high renewal rates. However, current financial challenges, such as declining quarterly revenue and increased net loss, are notable concerns. The company's efforts to manage costs and its pipeline of new and renewed contracts provide optimism for future performance.Q3-2025 Updates
Positive Updates
Strong Defense Sector Momentum
BIO-key is gaining significant traction in the defense sector with deployments among two of the top four largest global defense agencies. These contracts, including a new large deployment in the Middle East, signify substantial growth potential.
High Renewal Rates
The company enjoys very high renewal rates in excess of 90%, indicating strong customer satisfaction and retention.
New Product Launches
BIO-key introduced the FBI FAP 20 certified EcoID III fingerprint scanner and plans to release a significant update to the PortalGuard identity platform, enhancing its product offerings.
Cost Management and Financial Position
Operating expenses were reduced by over 10% through the first nine months of 2025, and the company raised approximately $3 million post-Q3, enhancing its cash liquidity.
Negative Updates
Revenue Decline
Q3 2025 revenue was $1.5 million, down from $2.1 million in Q3 2024, primarily due to the absence of large orders from the previous year.
Net Loss Increase
BIO-key reported a net loss of $965,000 in Q3 2025, compared to a net loss of $739,000 in Q3 2024.
Timing of Large Orders
Revenue variability is significantly affected by the timing of large orders, which can lead to unpredictability in quarterly performance.
Company Guidance
During the BIO-key International Third Quarter 2025 Conference Call, CEO Mike DePasquale and CFO Ceci Welch highlighted several key metrics and developments. The company reported Q3 2025 revenue of approximately $1.55 million, closely aligning with the first two quarters of the year, but reflecting a decrease of about $600,000 compared to Q3 2024. This decline was attributed to timing variability of large customer orders, with some orders expected in Q3 rolling over to Q4. BIO-key's gross margin remained strong at 77%, while operating expenses were reduced by over 10%, contributing to a net loss of $965,000 for the quarter. The company highlighted a high renewal rate exceeding 90% and discussed significant opportunities in defense and banking sectors, including a potential $1 million to $3 million renewal in early 2026 with a major banking customer. Additionally, BIO-key completed a $3 million funding round post-Q3, enhancing its cash liquidity to support growth initiatives. The management expressed confidence in closing 2025 strongly and achieving positive cash flow and profitability, supported by strategic expansions and a robust partner network.BIO-key International Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
45
Neutral
Cash Flow
35
Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
BIO-key International Technical Analysis
Negative
0.88
Price Trends
0.79
Negative
0.78
Negative
0.81
Negative
Market Momentum
-0.04
Positive
36.41
Neutral
12.82
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BKYI, the sentiment is Negative. The current price of 0.88 is above the 20-day moving average (MA) of 0.76, above the 50-day MA of 0.79, and above the 200-day MA of 0.81, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 36.41 is Neutral, neither overbought nor oversold. The STOCH value of 12.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BKYI.
BIO-key International Peers Comparison
UnderperformOutperform
Sector (―)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | ― | ― | ― | ― | ― | ― | |
54 Neutral | $39.63M | 26.19 | ― | ― | ― | ― | |
49 Neutral | $8.21M | -1.84 | -44.14% | ― | -14.21% | -20.44% | |
47 Neutral | $7.10M | -0.63 | -143.60% | ― | -1.19% | 86.72% | |
45 Neutral | $1.86M | >-0.01 | -233.66% | ― | -9.62% | 95.79% | |
41 Neutral | $56.05M | -0.64 | -164.48% | ― | 5.50% | 51.32% |
* Sector Average
BKYI
BIO-key International
0.64
-0.29
-31.18%
DGLY
Digital Ally
0.88
-1,059.52
-99.92%
SPCB
SuperCom
9.16
5.67
162.46%
IVDA
Iveda Solutions
0.88
-1.47
-62.55%
VRME
VerifyMe
0.70
0.07
11.11%
KSCP
Knightscope Inc Class A
4.32
-8.76
-66.97%
BIO-key International Corporate Events
Delistings and Listing ChangesStock SplitRegulatory Filings and Compliance
BIO-key Granted Extension by Nasdaq for Compliance
Neutral
Nov 7, 2025
On May 9, 2025, BIO-key International received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement of $1.00 per share. Despite not regaining compliance by November 6, 2025, Nasdaq granted the company an additional 180 days, until May 4, 2026, to meet the requirement. The company plans to monitor its stock price and may implement a reverse stock split to maintain its Nasdaq listing.
Private Placements and FinancingBusiness Operations and Strategy
BIO-key Secures $3.1M Through Warrant Agreement
Positive
Oct 30, 2025
On October 27, 2025, BIO-key International entered into a warrant exercise agreement with an institutional investor to adjust the terms of existing warrants, resulting in gross proceeds of approximately $3.1 million. The company plans to use these funds for working capital and corporate purposes, including debt repayment. Additionally, BIO-key finalized exchange agreements with Streeterville Capital, settling a secured promissory note by issuing shares of common stock, effectively paying off the original note.
Private Placements and Financing
BIO-key International Secures $1.13M Note Agreement
Neutral
Oct 3, 2025
On September 30, 2025, BIO-key International, Inc. entered into a note purchase agreement with Streeterville Capital, LLC, resulting in the issuance of a $1,130,000 senior secured promissory note. The company received $1,000,000 in funding after deductions, which will be used for general working capital. The note, due in eighteen months, carries a nine percent interest rate and includes various terms for repayment and default conditions, impacting the company’s financial obligations and operational flexibility.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.